



Press Release

New Influenza Vaccine Application

Münster, Germany, 11 January 2013

Cilian AG, an innovative biotechnology company based in Münster, Germany is the inventor and developer of a new, recombinant vaccine directed against influenza for seasonal or pandemic use (brand name: CiFlu[®]). This is a sub-unit vaccine developed with Cilian's proprietary CIPEX system, a system utilizing the unique abilities of Ciliates.

Earlier in 2012, Cilian established a collaboration with ProInnova to develop CiFlu[®] for human application.

Commencing in January 2013, Cilian is also pursuing its sub-unit vaccine concept for application in the veterinary field. This is being accomplished through a collaboration with a leading company in veterinary medicine. The significance of this endeavor lies in the parties' objective to help reduce viral infectious diseases in livestock used as food by humans.

For further information on Cilian, CIPEX and CiFlu[®], please visit www.cilian.com

Cilian AG:

Dr. Marcus Hartmann, CSO

Tel. +49 251 201 77 41

hartmann@cilian.de